# A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct05651932/  
OnCo record `nct05651932` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Gintemetostat run by K36 Therapeutics, Inc., now recruiting.

## Summary

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma is a phase 1 interventional study registered as NCT05651932 by K36 Therapeutics, Inc., with 165 participants planned, started 2023-02-22. Conditions recorded: Multiple Myeloma, Myeloma and Myeloma Multiple. Interventions recorded: Cohort A1 & A2: KTX-1001, Cohort B1 & B2: KTX-1001+Mezigdomide, Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®) and Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05651932
- Phase: 1
- Setting: A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma
- Sponsor: K36 Therapeutics, Inc.
- Enrolled: 165

## Sources

- ClinicalTrials.gov NCT05651932: https://clinicaltrials.gov/study/NCT05651932

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Gintemetostat](https://onco.cc/drugs/gintemetostat/)
- companies: [K36 Therapeutics](https://onco.cc/companies/k36-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05651932.json